CDTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CDTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cidara Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1. Operating Margin %Cidara Therapeutics's Operating Margin % for the quarter that ended in Sep. 2024 was %. As of today, Cidara Therapeutics's Piotroski F-Score is 3.
For the Biotechnology subindustry, Cidara Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cidara Therapeutics's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Cidara Therapeutics's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Cidara Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Cidara Therapeutics's Operating Margin % for the quarter that ended in Sep. 2024 is calculated as:
Operating Margin % | = | Operating Income (Q: Sep. 2024 ) | / | Revenue (Q: Sep. 2024 ) |
= | -17.394 | / | 0 | |
= | % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Cidara Therapeutics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Thank you for viewing the detailed overview of Cidara Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Leslie Tari | officer: Chief Scientific Officer | C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR SUITE 101, SAN DIEGO CA 92121 |
Taylor Sandison | officer: Chief Medical Officer | 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Jeffrey Stein | director, officer: President & CEO | 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Shane Ward | officer: CHIEF LEGAL OFFICER | C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025 |
Preetam Shah | officer: CFO & CBO | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019 |
Paul Daruwala | officer: Chief Medical Officer | 6310 NANCY RIDGE DR, SAN DIEGO CA 92121 |
Brady Johnson | officer: Dir. of Finance & Controller | 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Timothy R Franson | director | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Carin Canale-theakston | director | C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR STE 101 CA 92121 |
Bonnie L Bassler | director | REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591 |
James E. Levine | officer: Chief Financial Officer | 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142 |
Theodore R Schroeder | director | 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Chrysa Mineo | director | 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
David L Gollaher | director | 6310 NANCY RIDGE DR, SAN DIEGO CA 92121 |
Daniel D Burgess | director | C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121 |
From GuruFocus
By Marketwired • 11-07-2024
By Business Wire • 04-25-2024
By GlobeNewswire • 08-19-2024
By Marketwired • 10-16-2024
By Marketwired • 09-19-2024
By Marketwired • 05-14-2024
By Marketwired • 09-12-2024
By Marketwired • 05-15-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.